By Fineline Cube Sino Biopharmaceutical Ltd (HKG: 1177) announced first patient enrollment in the Phase II Kylo-11-II-C01 study evaluating Kylo-11, a novel siRNA drug targeting lipoprotein(a) [Lp(a)], in patients with atherosclerotic cardiovascular disease (ASCVD) and elevated Lp(a) levels.
Clinical Milestone
| Parameter | Detail |
|---|---|
| Study | Kylo-11-II-C01 |
| Phase | Phase II |
| First Patient | Enrolled April 2026 |
| Product | Kylo-11 (siRNA therapeutic) |
| Target | LPA (lipoprotein(a)) |
| Indication | ASCVD with elevated Lp(a) |
Technology Platform & Differentiation
- Platform: MVIP Delivery Platform – China’s first globally patented siRNA delivery technology
- Innovation: World’s first dual-conjugated siRNA delivery technology
- Key Features:
- Efficient cellular delivery enhancing tissue penetration
- Protection of antisense strand from exonuclease degradation
- Enhanced in vivo stability prolonging therapeutic activity
- Reduced plasma degradation of antisense strand improving bioavailability
- Clinical Advantage: Ultra-long-lasting effects enabling extended dosing intervals vs. conventional siRNA therapies
Mechanism of Action
- Target: LPA gene – encodes apolipoprotein(a), a causal risk factor for ASCVD independent of LDL cholesterol
- Mechanism: siRNA-mediated gene silencing reduces hepatic Lp(a) production
- Unmet Need: ~20% of global population has elevated Lp(a); no approved targeted therapies currently available
Market Context & Outlook
- Lp(a) Inhibitor Market: Projected US$10‑15 billion peak opportunity; validated by Novartis pelacarsen and Amgen olpasiran Phase II data
- Competitive Landscape:
| Company | Asset | Mechanism | Status |
|---|---|---|---|
| Novartis | Pelacarsen | ASO (antisense oligonucleotide) | Phase III (HORIZON) |
| Amgen | Olpasiran | siRNA | Phase II |
| Sino Biopharm | Kylo-11 | siRNA (MVIP platform) | Phase II (initiated) |
- Differentiation: MVIP platform’s dual-conjugation technology may offer superior durability and potency vs. first-generation siRNA delivery systems
- Strategic Value: First-mover position in China siRNA cardiovascular space; platform applicable to hepatic-targeted gene silencing across metabolic and rare diseases
- Revenue Potential: Peak China sales estimated at RMB 2‑3 billion (US$280‑420 million) by 2033 assuming 2029‑2030 launch and 15‑20% penetration in eligible ASCVD population
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical trial outcomes, platform validation, and commercial projections for Kylo-11. Actual results may differ due to risks including efficacy failures, safety signals, competitive advances from Novartis/Amgen programs, and regulatory requirements for novel siRNA delivery technologies.-Fineline Info & Tech